Aquinox Pharmaceuticals Inc. (AQXP) Stock Rating Reaffirmed by Leerink Swann
Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP)‘s stock had its “buy” rating reissued by equities research analysts at Leerink Swann in a research note issued to investors on Friday. They presently have a $24.00 target price on the stock. Leerink Swann’s target price indicates a potential upside of 68.90% from the stock’s current price.
Several other brokerages have also recently weighed in on AQXP. Needham & Company LLC reiterated a “buy” rating on shares of Aquinox Pharmaceuticals in a research report on Thursday, November 10th. Zacks Investment Research upgraded Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 4th. Canaccord Genuity reiterated a “buy” rating and issued a $22.00 price target on shares of Aquinox Pharmaceuticals in a research report on Wednesday, August 17th. Finally, Jefferies Group lifted their price target on Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the company a “hold” rating in a research report on Friday, August 5th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Aquinox Pharmaceuticals currently has an average rating of “Buy” and an average price target of $20.00.
Aquinox Pharmaceuticals (NASDAQ:AQXP) opened at 14.21 on Friday. The firm’s market cap is $244.58 million. Aquinox Pharmaceuticals has a 12-month low of $6.01 and a 12-month high of $15.76. The stock’s 50 day moving average price is $12.02 and its 200-day moving average price is $9.55.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its quarterly earnings data on Wednesday, November 9th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.12. Equities research analysts anticipate that Aquinox Pharmaceuticals will post ($2.13) earnings per share for the current fiscal year.
In other Aquinox Pharmaceuticals news, major shareholder Bros. Advisors Lp Baker acquired 2,783,605 shares of the company’s stock in a transaction that occurred on Tuesday, September 20th. The stock was bought at an average price of $12.25 per share, with a total value of $34,099,161.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 3.00% of the company’s stock.
A number of large investors have recently modified their holdings of the company. Tower Research Capital LLC TRC raised its stake in shares of Aquinox Pharmaceuticals by 227,925.0% in the third quarter. Tower Research Capital LLC TRC now owns 9,121 shares of the company’s stock valued at $122,000 after buying an additional 9,117 shares during the period. Bank of Montreal Can purchased a new stake in shares of Aquinox Pharmaceuticals during the second quarter valued at about $166,000. Morgan Stanley raised its stake in shares of Aquinox Pharmaceuticals by 41.5% in the third quarter. Morgan Stanley now owns 12,715 shares of the company’s stock valued at $169,000 after buying an additional 3,732 shares during the period. HighTower Advisors LLC purchased a new stake in shares of Aquinox Pharmaceuticals during the third quarter valued at about $257,000. Finally, Highbridge Capital Management LLC purchased a new stake in shares of Aquinox Pharmaceuticals during the third quarter valued at about $274,000. 67.13% of the stock is owned by hedge funds and other institutional investors.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.
Receive News & Stock Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.